Payment overview · 2025
General Payments
$629.45
33 reported records · 10 companies
Healthcare provider profile · identity verified
Michael G. Sherman, M.D.
Allopathic & Osteopathic Physicians|Pediatrics · WEST LINN, OR · NPI 1205866589
Verified facts
What the public records show
CMS Open Payments records show Michael G. Sherman, M.D. received $629.45 in general payments during 2025 across 33 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 39.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $246.45 | 39.1% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $98.57 | 15.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.01 | 11.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.85 | 8.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.75 | 5.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.45 | 4.8% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $29.50 | 4.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.27 | 4.7% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $24.30 | 3.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.30 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $629.45 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $246.45 | 12 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $98.57 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.43 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.43 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.43 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $31.20 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.45 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $29.27 | 2 | 2025 |
Source payment records
|
|||||
| Padcev Normalized: padcev |
Drug | Astellas Pharma US Inc | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 269 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 49 |
| Losartan Potassium | Losartan Potassium | 171 | 55 |
| Lisinopril | Lisinopril | 160 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 153 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 29 |
| Gabapentin | Gabapentin | 94 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 26 |
| Eliquis | Apixaban | 75 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 24 |
| Tramadol Hcl | Tramadol Hcl | 70 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 17 |
| Metformin Hcl | Metformin Hcl | 59 | 16 |
| Omeprazole | Omeprazole | 58 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 16 |
| Furosemide | Furosemide | 50 | 15 |
| Alprazolam | Alprazolam | 47 | 14 |
| Sertraline Hcl | Sertraline Hcl | 47 | 14 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Prednisone | Prednisone | 40 | 14 |
| Montelukast Sodium | Montelukast Sodium | 39 | 12 |
| Meloxicam | Meloxicam | 38 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 11 |
| Trazodone Hcl | Trazodone Hcl | 36 | 14 |
| Carvedilol | Carvedilol | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | 14 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Estradiol | Estradiol | 26 | 11 |
| Indapamide | Indapamide | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $629.45 · 33 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, BEXSERO, CAPVAXIVE, COMIRNATY, GARDASIL 9, Kerendia, M-M-R II, Ozempic, PAXLOVID, PEDIARIX, PREVNAR 20, Padcev, REXULTI, REZDIFFRA, The Cologuard Plus Collection Kit, VAXNEUVANCE, Xtandi | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error